Metformina + Vildagliptina Bluepharma

Metformin hydrochloride and vildagliptin, the active ingredients in Metformina + Vildagliptina Bluepharma, are a biguanide and a DPP‑4 inhibitor presented as oral tablets for oral use. They treat type 2 diabetes mellitus in adult patients.

GNH USA supplies Metformina + Vildagliptina Bluepharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Vildagliptina is indicated for the management of type 2 diabetes mellitus and related metabolic disorders.

- Type 2 diabetes mellitus: improves glycemic control when used alone or with other antidiabetic agents. - Metabolic syndrome (as part of diabetes management): helps lower fasting glucose and HbA1c levels. - Adjunct to diet and exercise: supports blood‑sugar regulation in adults with type 2 diabetes.

The combination may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or dyspepsia. - Diarrhea: loose stools occurring especially after treatment initiation. - Headache: mild to moderate intensity. - Metallic taste: transient alteration in taste perception. - Fatigue: feeling of tiredness without obvious cause. - Skin rash: mild erythematous eruptions.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Acute pancreatitis: sudden inflammation of the pancreas. - Hepatic failure: marked liver enzyme elevation or dysfunction. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction. - Anaphylactic reaction: rare systemic allergic response.

Before prescribing Metformina + Vildagliptina, clinicians should consider several safety factors.

- Renal function: assess eGFR and avoid use in severe renal impairment. - Hepatic disease: evaluate liver function because lactic acidosis risk rises. - Hypoglycaemia risk: monitor closely when combined with insulin or sulfonylureas. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Drug interactions: review concomitant medications for possible synergistic effects. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Metformina + Vildagliptina may interact with several medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycaemia. - Iodinated contrast agents: may precipitate renal dysfunction with metformin. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise vildagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Alcohol: potentiates risk of lactic acidosis. - Diuretics: may affect renal clearance of metformin, requiring dose adjustment.